ixazomib-pomalidomide-dexamethasone

Phase 2Small molecule

ixazomib-pomalidomide-dexamethasone is one of 3 small molecule programs targeting Multiple Myeloma in Relapse. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple Myeloma in RelapseActive, not recruiting

Multiple Myeloma in RelapsePhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Multiple Myeloma in Relapse

#DrugCompanyPhaseTrials

Xpovio

KKaryopharm Therapeutics Inc

Phase 2

1 2

Rapamycin

MMaastricht Radiation Oncology

Phase 1

1 3

ixazomib-pomalidomide-dexamethasone

TTel-Aviv Sourasky Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Multiple Myeloma in Relapse

NCT04790474

Clinical

Trials by Indication[1]

Multiple Myeloma in Relapse1 trial

A Single-arm, Multisite, Prospective Study of Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Previously Treated With Daratumumab, Lenalidomide and Bortezomib (IPoD-790 Study)

Active, not recruiting·TTel-Aviv Sourasky Medical Center·Phase 2·NCT04790474·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ixazomib-pomalidomide-dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ixazomib-pomalidomide-dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ixazomib-pomalidomide-dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tel-Aviv Sourasky Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTel-Aviv Sourasky Medical Center

ixazomib-pomalidomide-dexamethasone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Multiple Myeloma in Relapse1 trial

References

Drug Info

Quick Facts

Related News